Swati Goel

Swati Goel

Auto-generated profile, based on publicly available information

Swati Goel

11Department of Medical Oncology, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 September 2020 in Blood Advances
Verified
Journal Article
Open access
PDF file
SOStephen T. Oh
Stephen T. Oh
MTMoshe Talpaz
Moshe Talpaz
AGAaron T. Gerds
Aaron T. Gerds
VGVikas Gupta
Vikas Gupta
SVSrdan Verstovsek
Srdan Verstovsek
CBCarrie Baker Brachmann
Carrie Baker Brachmann
Momelotinib (MMB) is a JAK1/2 and ACVR1 inhibitor with demonstrated clinical activity in all 3 hallmarks of myelofibrosis (MF): anemia, constitutional symptoms, and splenomegaly. In this phase 2 open-label translational biology study (NCT02515630) of 41 transfusion-dependent patients with MF, we explored mechanisms underlying the favorable activity of MMB on MF-associated iron-restricted anemia, including its impact on serum hepcidin levels, and markers of iron storage and availability, erythropoiesis, and inflammation. A transfusion-independent response (TI-R), defined as red blood cell transfusion independence (TI) ≥12 weeks at any time on study, occurred in 17 patients (41%; 95% confidence interval [CI], 26%-58%), including 14 patients (34%; 95% CI, 20%-51%) who achieved TI-R by week 24. In addition, 78% of TI nonresponse (TI-NR) patients achieved a ≥50% decrease in transfusion requirement for ≥8 weeks. Adverse events (AEs) were consistent with previous studies of MMB in MF, with cough, diarrhea, and nausea as the most common. Twenty-one patients experienced grade ≥3 AEs, most commonly anemia and neutropenia. Consistent with preclinical data, daily MMB treatment led to an acute and persistent decrease in blood hepcidin associated with increased iron availability and markers of erythropoiesis. Baseline characteristics associated with TI-R were lower inflammation and hepcidin as well as increased markers of erythropoiesis and bone marrow function. Overall, the study demonstrates that MMB treatment decreases hepcidin in conjunction with improving iron metabolism and erythropoiesis, suggesting a mechanistic explanation for the reduced transfusion dependency observed in transfusion-dependent MF patients treated with MMB, thereby addressing the key unmet medical need in the MF population.

5 August 2020 in International Forum of Allergy & Rhinology
Verified
Journal Article
Closed access
PDF file
FSFatemeh Saheb Sharif‐Askari
Fatemeh Saheb Sharif‐Askari
NANarjes Saheb Sharif Askari
Narjes Saheb Sharif Askari
SGSwati Goel
Swati Goel
SFSamer Fakhri
Samer Fakhri
SASaleh Al‐Muhsen
Saleh Al‐Muhsen
RHRabih Halwani
Rabih Halwani

29 May 2020 in Clinical Lymphoma Myeloma and Leukemia
Verified
Journal Article
Closed access
ACAlexander Coltoff
Alexander Coltoff
RMRuben A. Mesa
Ruben A. Mesa
JGJason Gotlib
Jason Gotlib
JSJessica Shulman
Jessica Shulman
RRRaajit K. Rampal
Raajit K. Rampal
JMJohn Mascarenhas
John Mascarenhas

18 March 2024 in Blood Advances
Verified
Journal Article
Open access
PDF file
AYAbdulraheem Yacoub
Abdulraheem Yacoub
UBUma Borate
Uma Borate
RRRaajit K. Rampal
Raajit K. Rampal
HAHaris Ali
Haris Ali
EWEunice S. Wang
Eunice S. Wang
Naval DaverNaval Daver
Naval Daver
Ruxolitinib reduces spleen volume, improves symptoms, and increases survival in patients with intermediate- or high-risk myelofibrosis. However, suboptimal response may occur, potentially because of signaling via the phosphoinositide 3-kinase (PI3K)/protein kinase B pathway. This phase 2 study evaluated dosing, efficacy, and safety of add-on PI3Kδ inhibitor parsaclisib for patients with primary or secondary myelofibrosis with suboptimal response to ruxolitinib. Eligible patients remained on a stable ruxolitinib dose and received add-on parsaclisib 10 or 20 mg, once daily for 8 weeks, and once weekly thereafter (daily-to-weekly dosing; n = 32); or parsaclisib 5 or 20 mg, once daily for 8 weeks, then 5 mg once daily thereafter (all-daily dosing; n = 42). Proportion of patients achieving a ≥10% decrease in spleen volume at 12 weeks was 28% for daily-to-weekly dosing and 59.5% for all-daily dosing. Proportions of patients achieving ≥50% decrease at week 12 in Myelofibrosis Symptom Assessment Form and Myeloproliferative Neoplasms Symptom Assessment Form symptom scores were 14% and 18% for daily-to-weekly dosing, and 28% and 32% for all-daily dosing, respectively. Most common nonhematologic treatment-emergent adverse events were nausea (23%), diarrhea (22%), abdominal pain and fatigue (each 19%), and cough and dyspnea (each 18%). New-onset grade 3 and 4 thrombocytopenia were observed in 19% of patients, each dosed daily-to-weekly, and in 26% and 7% of patients dosed all-daily, respectively, managed with dose interruptions. Hemoglobin levels remained steady. The addition of parsaclisib to stable-dose ruxolitinib can reduce splenomegaly and improve symptoms, with manageable toxicity in patients with myelofibrosis with suboptimal response to ruxolitinib. This trial was registered at www.clinicaltrials.gov as #NCT02718300.

22 April 2021 in ERJ Open Research
Verified
Journal Article
Open access
PDF file
FSFatemeh Saheb Sharif-Askari
Fatemeh Saheb Sharif-Askari
NANarjes Saheb Sharif Askari
Narjes Saheb Sharif Askari
SGSwati Goel
Swati Goel
BMBassam Mahboub
Bassam Mahboub
AAAbdul Wahid Ansari
Abdul Wahid Ansari
RHRabih Halwani
Rabih Halwani
Interleukin (IL)-19, a designated IL-20 subfamily cytokine, has been implicated in inflammatory disorders including rheumatoid arthritis, psoriasis and, lately, asthma. Here, through the analysis of transcriptomic datasets of lung tissue of large asthma cohorts, we report that IL-19 expression is upregulated in asthma and correlates with disease severity. The gene expression of IL-19 was significantly higher in lung tissue from patients with severe and mild/moderate asthma compared to healthy controls. IL-19 protein level, however, was significantly higher in the blood and saliva of patients with severe asthma compared to mild/moderate subgroups as measured by ELISA assay. IL-19 protein level was not affected by corticosteroid treatment in plasma. Our data provide insights into the potential use of IL-19 as a saliva marker for asthma severity and a potential therapeutic target.

15 February 2023 in Blood Advances
Verified
Journal Article
Open access
PDF file
NGNaseema Gangat
Naseema Gangat
AKAndrew Kuykendall
Andrew Kuykendall
NANajla H Al Ali
Najla H Al Ali
SGSwati Goel
Swati Goel
MAMaymona Abdelmagid
Maymona Abdelmagid
ATAyalew Tefferi
Ayalew Tefferi
Naseema Gangat, Andrew T Kuykendall, Najla H Al Ali, Swati Goel, Maymona Abdelmagid, Aref Al-Kali, Hassan B Alkhateeb, Kebede Begna, Abhishek A. Mangaonkar, Mar